ABL1 and acute lymphoblastic leukemia: All B-ALL cell lines that we tested showed different levels of sensitivity to BRD9 degrader treatment: SEM, SEMK2, RS4;11, and REH (IC50s in the range of 1–10 nM); 697 and p190BCR-ABL-positive SUP-B15 (IC50s close to 1 nM); NALM6 and RCH-ACV (IC50s in the 10–100 nM range) (Fig. 4A, Supplementary Figs. 5A–E and 6A–D).